These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL. Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [Abstract] [Full Text] [Related]
3. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Tykodi SS, Warren EH, Thompson JA, Riddell SR, Childs RW, Otterud BE, Leppert MF, Storb R, Sandmaier BM. Clin Cancer Res; 2004 Dec 01; 10(23):7799-811. PubMed ID: 15585611 [Abstract] [Full Text] [Related]
11. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Biol Blood Marrow Transplant; 2015 Jul 01; 21(7):1299-307. PubMed ID: 25797174 [Abstract] [Full Text] [Related]
15. New developments in allotransplant immunology. Barrett AJ, Rezvani K, Solomon S, Dickinson AM, Wang XN, Stark G, Cullup H, Jarvis M, Middleton PG, Chao N. Hematology Am Soc Hematol Educ Program; 2003 Jul 01; ():350-71. PubMed ID: 14633790 [Abstract] [Full Text] [Related]
16. Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation. Nagler A, Or R, Naparstek E, Varadi G, Slavin S. Exp Hematol; 2000 Sep 01; 28(9):1096-104. PubMed ID: 11008023 [Abstract] [Full Text] [Related]
17. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF. Blood; 2001 Jun 01; 97(11):3390-400. PubMed ID: 11369628 [Abstract] [Full Text] [Related]